1 / 9

China Biopsy Market Forecast by Cancer Segment & Company Analysis

China has 40% higher motility rate compared to the United Kingdom and the United States. Imaging tests like X-rays and CT scans assist in discovering areas of concerns, but they canu2019t differentiate between cancerous and noncancerous cells. For the diagnosis of cancer, a biopsy is the only sure way to identify most cancers. According to Renub Research report, China Biopsy Market is expected to reach USD 8.1 Billion by the end of the year 2026.

renubresearch
Download Presentation

China Biopsy Market Forecast by Cancer Segment & Company Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. China Biopsy Market China Biopsy Market

  2. Report Description and Highlights Cancer is the leading cause of mortality in China. There approximately 4.3 Million cancer cases and 2.9 Million cancer death occurred over in 2018. So an average of 7 people was diagnosed with cancer, while 4 people died of cancer every minute in China. China has 40% higher motility rate compared to the United Kingdom and the United States. Imaging tests like X- rays and CT scans assist in discovering areas of concerns, but they can’t cancerous and noncancerous cells. For the diagnosis of cancer, a biopsy is the only sure way to identify most cancers. According to Renub Research report, China Biopsy Market is expected Billion by the end of the year 2026. differentiate between to reach USD 8.1 China Biopsy Market

  3. China Biopsy Market How COVID-19 affects China Biopsy Industry The Coronavirus outbreak has come as a massive blow on the biopsy diagnostics centres, hospitals, supply chain and clinical trials of the biopsy industry. As per our findings, the biopsy market in China got affected a bit from December 2019 to April 2020. Read the complete analysis of COVID-19 in our report. As for how this pandemic is affecting the biopsy industry in China and when it’s going to revive. Reasons for Growth in Cancer Cases and High Mortality Rate in China The rise in cancer cases has been driven by an ageing population and the prevalence of lifestyle factors such as smoking, stress and sedentary lifestyle. The prime reasons for the higher mortality in China are due to its low rate of early-stage cancers detection, and another reason is that China still has non-uniformed clinical cancer treatment strategies performed by different regions. Request a free sample copy of the report: https://www.renub.com/request- sample-page.php?gturl=china-biopsy-market-p.php China Biopsy Market

  4. China Biopsy Market Top 3 Types of Cancers in China Chinese population is mostly affected by three types of cancer Breast Cancer, Liver cancer, Colon and Rectum cancer. Breast cancer is one of the most common cancer among women in China. Our study also reveals that breast cancer rates are higher in urban areas of China than in rural areas. As with the rapid development of China’s economy, more and more people have moved from rural areas to large cities. This is a known fact that having more than one child lowers breast- cancer risk. But China had 1 child policy from 1979, and since most of the women work in the city, they have to follow the policy to avoid penalty. Although this one-child rule was repealed in 2015 with two- child policy rule, however, it will take 15 to 20 years for this policy to show any result. China Biopsy Market

  5. China Biopsy Market Renub Research report titled “China Biopsy Market, by Cancer Segment (Breast cancer, prostate cancer, lung cancer, liver cancer, thyroid cancer, kidney cancer, colon & rectum cancer, kidney cancer, leukemia, pancreas cancer, and bladder cancer), Volume of Biopsy and Patient Diagnosed Numbers, Company (C. R. Bard, Inc., Becton, Dickinson and Company, Cardinal Health, Inc, Boston Scientific Inc.)” provides an all-encompassing analysis on the Biopsy Market in China. Corporation and Hologic, 10 cancer segments have been studied in this report, and each cancer segment is covered from 3 points 1. Market 2. Volume of Biopsy 3. Patient Diagnosed China Biopsy Market

  6. China Biopsy Market Forecast for China Biopsy Market Share (%) - by Segment (2020 - 2026) Source: Renub Research Analysis Note: These are dummy figures; actual data given in the report China Biopsy Market

  7. China Biopsy Market Cancer Segments covered in the report 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Breast Cancer Prostate Cancer Lung Cancer Liver Cancer Thyroid Cancer Colon & Rectum Cancer Kidney Cancer Leukaemia Pancreas Cancer Bladder Cancer China Biopsy Market

  8. China Biopsy Market All the companies have been studied from three points Overview Recent Developments Sales Analysis • • • Company Analysis C. R. Bard, Inc. Becton, Dickinson and Company Cardinal Health, Inc Boston Scientific Corporation Hologic, Inc. • • • • • Request a free Brochure copy of the report: https://www.renub.com/request- brochure-page.php?gturl=china-biopsy-market-p.php China Biopsy Market

  9. China Biopsy Market Browse Related Report : Orthopedic Prosthetic Market Respiratory Care Devices Market Contact Us Tel: +1-678-302-0700 (US), +91-120-421-9822 (INDIA) Email: info@renub.com China Biopsy Market

More Related